Storck 1968.

Methods	Randomised clinical trial
Participants	Country: Sweden Number randomised: 43 Postrandomisation dropouts: not stated Revised sample size: 43 Average age: 59 years Women: 28 (65.1%) Acute interstitial oedematous pancreatitis: not stated Necrotising pancreatitis: not stated Mild pancreatitis: not stated Moderate pancreatitis: not stated Severe pancreatitis: not stated Persistent organ failure: not stated Infected pancreatitis: not stated Inclusion criteria: people with acute pancreatitis
Interventions	Group 1: aprotinin (n = 21), first half of the trial ‐ 50,000 to 100,000 units per day and then dose doubled for an average of 12 days Group 2: placebo (n = 22)
Outcomes	Mortality Follow‐up: not stated (probably until discharge)
Notes	Reasons for postrandomisation dropouts: not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available.
Allocation concealment (selection bias)	Low risk	Quote: "[s]ealed envelopes"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "double blind"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "double blind"
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: this information was not available.
Selective reporting (reporting bias)	High risk	Comment: either mortality or adverse events were not reported.
For profit‐bias	Unclear risk	Comment: this information was not available.
Other bias	Low risk	Comment: no other risk of bias